A pooled secondary analysis of DESTINY-Lung01 and DESTINY-Lung02 including 243 patients with previously-treated metastatic HER2+ NSCLC demonstrates robust systemic and intracranial activity with the approved 5.4-mg/kg dosing of trastuzumab-deruxtecan. | Jänne, JAMA Netw Open 2025
